Interleukin-28B Genotyping by Melt-Mismatch Amplification Mutation Assay PCR Analysis Using Single Nucleotide Polymorphisms rs12979860 and rs8099917, a Useful Tool for Prediction of Therapy Response in Hepatitis C Patients
- 1 July 2011
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 49 (7) , 2706-2710
Abstract
Several studies have identified associations between single nucleotide polymorphisms (SNPs) occurring near the interleukin-28B (IL-28B) gene and response to antiviral treatment among hepatitis C virus (HCV) patients. Here, we describe a reliable melt-mismatch amplification mutation assay (melt-MAMA) PCR-based genotyping method for IL-28B which can be used in the management of HCV patients, helping to better define the course of therapy.Keywords
This publication has 21 references indexed in Scilit:
- Baseline Prediction of Combination Therapy Outcome in Hepatitis C Virus 1b Infected Patients by Discriminant Analysis Using Viral and Host FactorsPLOS ONE, 2010
- Individualisation of antiviral therapy for chronic hepatitis CJournal of Gastroenterology and Hepatology, 2010
- Simultaneous Cocirculation of Both European Varicella-Zoster Virus Genotypes (E1 and E2) in Mexico CityJournal of Clinical Microbiology, 2010
- Contribution of Genome-Wide HCV Genetic Differences to Outcome of Interferon-Based Therapy in Caucasian American and African American PatientsPLOS ONE, 2010
- Genetic variation in IL28B and spontaneous clearance of hepatitis C virusNature, 2009
- A matched case‐controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological responseJournal of Medical Virology, 2009
- Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humansJournal of Clinical Investigation, 2008
- MAMA-PCR assay for the detection of point mutations associated with high-level erythromycin resistance in Campylobacter jejuni and Campylobacter coli strainsJournal of Microbiological Methods, 2005
- Global Burden of Disease (GBD) for Hepatitis CThe Journal of Clinical Pharmacology, 2004
- Natural history of chronic hepatitis CHepatology, 2002